Boston Scientific drives rival Nevro lower after remarks on neuromodulation

Oct. 26, 2022 1:43 PM ETNevro Corp. (NVRO)BSXBy: Dulan Lokuwithana, SA News Editor

Nevro Corp. headquarters in Silicon Valle

Sundry Photography/iStock Editorial via Getty Images

  • Nevro Corp. (NYSE:NVRO), a company focused on neuromodulation solutions, dropped at the open on Wednesday after its rival Boston Scientific (BSX) said that its Q3 sales for the pain treatment

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.